Funding Will Advance Trials of APL-2 in Paroxysmal Nocturnal Hemoglobinuria LOUISVILLE, KY., August 10, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today announced the closing of a $60 million Series E preferred stock financing led by Sectoral Asset Management. New …
Year: 2017
Fennec Announces $7.6 Million Private Placement of Common Shares Led by venBio Select Advisor
Fennec Announces $7.6 Million Private Placement of Common Shares Led by venBio Select Advisor RESEARCH TRIANGLE PARK, NORTH CAROLINA — (Marketwired) — 06/08/17 — Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) (the “Company” or “Fennec”), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric …
+1 212.937.4970